[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Guangzhou Women and Children's Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":597},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,25,0,[8,42,68,96,117,135,163,190,214,236,261,283,304,326,353,380,401,429,448,469,489,506,530,550,573],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100634923","multidimensional-dynamic-early-warning-system-for-neonatal-necrotizing-enterocolitis-a-multicenter-clinical-study-100634923",false,"NCT07545993","Multidimensional Dynamic Early Warning System for Neonatal Necrotizing Enterocolitis: A Multicenter Clinical Study","Construction of a Multidimensional Dynamic Early Warning System for Genetic-Immune-Inflammatory Disorders in Precision Prevention and Control of Neonatal Necrotizing Enterocolitis: A Multicenter Clinical Study","Inclusion Criteria:\n\n* Preterm infants with gestational age \\\u003C32 weeks\n* Admission to the neonatology department of the lead institution or participating institutions\n* Parental consent to participate in the study and approval for genetic testing using residual samples from routine blood draws.\n* Possession of complete perinatal and hospitalization records.\n\nExclusion Criteria:\n\n* Congenital malformations, well-defined clinical syndromes, or chromosomal abnormalities\n* Death within 7 days after birth or voluntary discharge\n* Patients with confirmed positive diagnosis of pathogenic genes and interpretable major clinical phenotypes\n* Only one case of identical multiple births was retained for analysis to avoid genetic background overlap","ALL","0 Days","3 Months",{"count":20,"type":21},1050,"ESTIMATED","6 Months","OBSERVATIONAL","Necrotizing enterocolitis (NEC) is one of the most severe gastrointestinal emergencies in preterm infants, characterized by insidious onset, rapid progression, and high mortality. It can lead to serious adverse outcomes such as intestinal perforation, short bowel syndrome, and neurodevelopmental disorders, making it a critical condition that significantly impacts the survival quality and long-term prognosis of preterm infants.With the advancement of perinatal medicine in China, the survival rates of extremely low and very low birth weight infants have been continuously improving. NEC has become a critical bottleneck constraining the quality of care and long-term prognosis for preterm infants.\n\nPrevious studies have demonstrated that various perinatal and early postnatal factors, including gestational age, birth weight, infection, feeding methods, blood transfusion, mechanical ventilation, and antibiotic exposure, are associated with the occurrence of NEC. However, these clinical factors still fail to adequately explain the interindividual variations in NEC incidence risk and disease severity under similar clinical exposure conditions.Existing NEC prediction models primarily rely on static baseline variables for one-time risk assessment, lacking dynamic risk updates during hospitalization, and most are derived from single-center retrospective studies.\n\nWith the application of clinical exome sequencing (CES), the role of genetic factors in susceptibility to NEC has gradually attracted attention.The research team has previously conducted NEC risk gene screening based on CES, genetic burden analysis, and exploration of genetic-clinical factor interactions, suggesting that genetic information can provide important supplementation for NEC risk assessment.Meanwhile, dynamic changes in immune-inflammatory markers such as peripheral blood eosinophils, NLR, absolute neutrophil count, and platelet count may already exhibit abnormalities prior to the onset of NEC, providing repeatable, low-cost, and clinically available signals for early identification.Based on this, this study aims to establish a multidimensional dynamic early warning system for NEC integrating single-center preliminary genetic research foundations with multi-center retrospective\u002Fprospective validation resources. This initiative seeks to enhance the identification capability of high-risk individuals and provide evidence for subsequent precision prevention and control as well as stratified management.",[26],"NEC - Necrotizing Enterocolitis",[28,29,30],"preterm","neonate","early warning system","NOT_YET_RECRUITING","2026-04-15",{"date":34,"type":35},"2026-04-22","ACTUAL",{"date":32,"type":21},{"date":38,"type":21},"2029-12-31",{"name":40,"class":41},"Guangzhou Women and Children's Medical Center","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100607549","early-phase-1-yolt-204-in-patients-with-hemoglobinopathies-100607549","NCT07190001","YOLT-204 in Patients With Hemoglobinopathies","An Exploratory Clinical Study to Evaluate the Safety and Efficacy of YOLT-204 in Patients With Hemoglobinopathies (β-thalassemia and Sickle-cell Disease)","Inclusion Criteria:\n\n* Aged 3-17 years (inclusive); any sex.\n* The subject and\u002For his\u002Fher legally authorized guardian\u002Frepresentative must fully understand the study and voluntarily sign a written informed-consent form.\n* Karnofsky Performance Status (KPS) ≥ 70 (if ≥ 16 years old) or Lansky Performance Scale (LPS) ≥ 70 (if \\\u003C 16 years old).\n* Detailed medical records of red-cell transfusions during the 2 years before informed-consent signature must be available, including volume or units transfused and pre-\u002Fpost-transfusion red-cell and hemoglobin levels.\n* No severe hematopoietic dysfunction; cardiac, pulmonary, hepatic, and renal function essentially normal.\n* Coagulation: international normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 × upper limit of normal (ULN).\n* Renal function: serum creatinine ≤ 1.5 × ULN; if creatinine \\> 1.5 × ULN, calculated creatinine clearance \\> 50 mL\u002Fmin by the Schwartz formula.\n* Hepatic function: alanine aminotransferase (ALT) ≤ 3 × ULN and aspartate aminotransferase (AST) ≤ 3 × ULN.\n* Cardiac function: left-ventricular ejection fraction (LVEF) ≥ 50 %.\n* Good compliance; willing to adhere to visit schedules, study procedures, laboratory tests, and other protocol requirements.\n* Agrees to use at least one highly effective contraceptive method from informed-consent signature through the end of the main study (Week 52 visit).\n* Willing to participate in long-term follow-up.\n* Screening genotype shows HbSS or HbSβ0; prior reports acceptable if assessed as adequate by the investigator.\n* If on L-glutamine, regimen must have been stable for ≥ 3 months before study-drug administration; if on hydroxyurea, must have discontinued ≥ 8 weeks before study-drug administration.\n* Meets severe SCD criteria: despite optimal supportive therapy (including, but not limited to, analgesics and hydroxyurea), at least two of the following events occurred in the 12 months before screening:\n* Severe intermittent acute pain requiring healthcare-provider management;\n* Acute chest syndrome with new pulmonary infiltrate on chest imaging plus pneumonia-like symptoms, pain, or fever;\n* Splenic sequestration crisis manifested by enlarged spleen, left upper-quadrant pain, and acute Hb drop \\> 20 g\u002FL.\n\nExclusion Criteria:\n\n* 1.History of multiple drug allergies or hypersensitivity to oligonucleotides or lipid nanoparticles (LNP).\n\n  2.Clinically significant active bacterial, viral, fungal, or parasitic infection at screening, as judged by the investigator.\n\n  3.White blood cell (WBC) count \\\u003C 3 × 10⁹\u002FL and\u002For platelet count \\\u003C 100 × 10⁹\u002FL at screening.\n\n  4.Uncorrected bleeding diathesis. 5.Massive splenomegaly at screening (spleen edge below the umbilicus or \\> 4 cm below the costal margin) deemed by the investigator to preclude enrollment.\n\n  6.Serum ferritin ≥ 5 000 ng\u002FmL, or MRI T2\\* evidence of severe cardiac or hepatic iron overload.\n\n  7.Positive for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus antibody, anti-HIV antibody, or specific anti-Treponema pallidum antibody.\n\n  8.Prior hematopoietic stem-cell transplantation, gene therapy, or gene-editing therapy.\n\n  9.Participation in another clinical trial and receipt of investigational product within 3 months before first dose of study drug.\n\n  10.Current or prior malignancy, myeloproliferative disorder, or immunodeficiency disease.\n\n  11.Severe psychiatric illness precluding cooperation; clinically significant pulmonary hypertension requiring medical intervention; recent malaria; first-degree relative with hematologic malignancy.\n\n  12.Positive pregnancy test, pregnancy, or lactation in female subjects at screening.\n\n  13.Any condition (past or present) that, in the investigator's opinion, could confound results, compromise participation, or render the patient unsuitable for the study.\n\n  14.Use within 3 months before study drug: erythropoietin (EPO), thalidomide, hydroxyurea, luspatercept, or similar agents.\n\n  15.In subjects ≥ 12 years, abnormal transcranial Doppler (TCD) with middle cerebral or internal carotid artery velocity ≥ 200 cm\u002Fs.\n\n  16.History of moyamoya disease or imaging findings consistent with moyamoya at screening, assessed by the investigator as conferring bleeding risk.","3 Years","17 Years",{"count":52,"type":21},18,"INTERVENTIONAL",[55],"EARLY_PHASE1","This is a single-arm, open-label, single-dose, dose-escalation trial that plans to enrol 3-18 patients with transfusion-dependent β-thalassaemia (TDT) or sickle-cell disease (SCD). Its primary aims are to evaluate the safety and tolerability of a single administration of YOLT-204 and to obtain preliminary data on its effect on plasma fetal-haemoglobin levels. The main-study screening period may last up to 60 days; the treatment day is Day 0 (D0). Safety follow-up continues through Week 52 post-dose. After completion of the main study, participants will enter long-term follow-up extending to 15 years post-dose.",[58],"Hemoglobinopathies (Transfusion-dependent β-thalassemia and Sickle Cell Disease)","2025-09-16",{"date":61,"type":35},"2025-09-24",{"date":63,"type":21},"2025-09-30",{"date":65,"type":21},"2027-04-30",{"name":40,"class":41},1,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":67},"100597936","non-helium-magnetoencephalography-in-autism-spectrum-disorder-100597936","NCT07064967","Non-Helium Magnetoencephalography in Autism Spectrum Disorder","Non-Helium Magnetoencephalography for Identifying Neurobiological Features and Functional Biomarkers in Children With Autism Spectrum Disorder: An Observational Cohort Study","Inclusion Criteria:\n\n* Boys aged 6 to 12 years;\n* Diagnosis of Autism Spectrum Disorder meeting DSM-5 criteria;\n* Intelligence quotient (IQ) score \\> 70 (assessed via Wechsler Intelligence Scale for Children or other validated cognitive test);\n* Sufficient compliance to participate in MEG experiments.\n\nExclusion Criteria:\n\n* Comorbid neurological disorders, genetic syndromes, or severe developmental disabilities;\n* Metallic implants that may interfere with MEG signal acquisition;\n* Current use of antipsychotic medications or sedatives.",true,"MALE","6 Years","12 Years",{"count":80,"type":21},80,"The goal of this observational study is to learn how brain activity in children with autism spectrum disorder (ASD) differs from typical developing children using magnetoencephalography (MEG).\n\nThe main questions this study aims to answer are:\n\nDo children with ASD show different patterns of neural oscillation compared to typically developing children? Can MEG identify specific brain features that help ASD diagnosis?\n\nParticipants will undergo MEG scan in both resting and tasking state, and their brain activity will be analyzed for characteristic neural oscillations and connectivity patterns.\n\nThis study may help develop better tools for early ASD diagnosis.",[83],"Autism Spectrum Disorder (ASD)",[85,86],"Autism Spectrum Disorder","Magnetoencephalography","RECRUITING","2025-07-03",{"date":90,"type":35},"2025-07-15",{"date":92,"type":35},"2024-11-05",{"date":94,"type":21},"2027-12-31",{"name":40,"class":41},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":103,"enrollmentInfo":104,"targetDuration":106,"studyType":23,"phases":4,"briefSummary":107,"conditions":108,"keywords":110,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":115,"leadSponsor":116,"locationsCount":67},"100597894","non-helium-magnetoencephalography-in-pediatric-refractory-epilepsy-100597894","NCT07064421","Non-Helium Magnetoencephalography in Pediatric Refractory Epilepsy","Non-Helium Magnetoencephalography for Clinical Management of Refractory Epilepsy in Children: An Observational Cohort Study","Inclusion Criteria:\n\n1. Age range: 3-18 years old;\n2. Clinically diagnosed with refractory epilepsy;\n3. Capable of cooperating with magnetoencephalography evaluation and recording.\n\nExclusion Criteria:\n\n1. Patients with serious comorbidities or neurological or psychiatric disorders that affect magnetoencephalography examination.\n2. Patients using drugs that affect central nervous system function;\n3. Patients who are not suitable for surgical procedures;\n4. Patients with progressive neurological disorders.","18 Years",{"count":105,"type":21},100,"12 Months","The goal of this observational study is to evaluate the effectiveness of Magnetoencephalography (MEG) in the preoperative assessment of children with refractory epilepsy, particularly in identifying the seizure focus, and to compare it with the gold standard methods of Stereo-electroencephalography (SEEG) and Electrocorticography (ECoG).\n\nThe main questions this study aims to answer are:\n\n1. How consistent is MEG with SEEG\u002FECoG in locating the epileptic focus in children with refractory epilepsy?\n2. What is the clinical efficacy of MEG in identifying epileptic foci?\n\nParticipants will:\n\n1. Be divided into 2 groups: the case group and the control group. Participants in the case group will undergo both MEG and SEEG\u002FECoG for preoperative assessment, while patients in the control group will undergo only SEEG\u002FECoG before surgery.\n2. Be followed up at 1, 3, 6, and 12 months after surgery to assess seizure control, neurological function, and quality of life.",[109],"Refractory Epilepsy in Children",[111,86],"Epilepsy",{"date":113,"type":35},"2025-07-14",{"date":92,"type":35},{"date":94,"type":21},{"name":40,"class":41},{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":103,"enrollmentInfo":124,"targetDuration":106,"studyType":23,"phases":4,"briefSummary":125,"conditions":126,"keywords":128,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":133,"leadSponsor":134,"locationsCount":67},"100588618","non-helium-magnetoencephalography-in-pediatric-brain-tumors-100588618","NCT06943742","Non-Helium Magnetoencephalography in Pediatric Brain Tumors","Non-Helium Magnetoencephalography for Clinical Management of Pediatric Brain Tumors : An Observational Cohort Study","Inclusion Criteria:\n\n* Age range: 3-18 years old;\n* Clinically diagnosed with brain tumor;\n* Capable of cooperating with magnetoencephalography evaluation and recording.\n\nExclusion Criteria:\n\n* Patients with serious comorbidities or neurological or psychiatric disorders that affect magnetoencephalography examination.\n* Patients using drugs that affect central nervous system function;\n* Patients who are not suitable for surgical procedures;\n* Patients with progressive neurological disorders.",{"count":105,"type":21},"This observational study aims to evaluate the effectiveness of magnetoencephalography (MEG) in the preoperative assessment of pediatric brain tumors, particularly in determining the extent of resection, and compare it with computed tomography (CT) and magnetic resonance imaging (MRI).\n\nThe main questions this study aims to answer are:\n\nWhat is the consistency between MEG and CT\u002FMRI in localizing pediatric brain tumors? What is the clinical efficacy of MEG in determining the extent of resection of pediatric brain tumors preoperatively?\n\nParticipants will:\n\nUndergo both MEG and CT\u002FMRI examinations for preoperative assessment, and the extent of tumor resection will be determined by the comprehensive results of the above examinations.\n\nBe followed up with MEG and CT\u002FMRI at 1, 3, and 6 months after surgery, along with neurological and quality-of-life assessments.",[127],"Pediatric Brain Tumor",[86,127],"2025-04-22",{"date":131,"type":35},"2025-04-24",{"date":92,"type":35},{"date":94,"type":21},{"name":40,"class":41},{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":16,"minAge":141,"maxAge":103,"enrollmentInfo":142,"targetDuration":4,"studyType":53,"phases":144,"briefSummary":147,"conditions":148,"keywords":152,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":4},"100589021","phase-1-a-clinical-trial-on-autologous-nk-cells-combined-with-gd2-monoclonal-antibody-in-the-treatment-of-children-with-newly-diagnosed-high-risk-or-relapsedrefractory-neuroblastoma-100589021","NCT06948994","A Clinical Trial on Autologous NK Cells Combined With GD2 Monoclonal Antibody in the Treatment of Children With Newly Diagnosed High-risk or Relapsed\u002FRefractory Neuroblastoma","Inclusion Criteria:\n\n1. Age 1-18 years (including 18 years), gender not restricted;\n2. Diagnosed with high-risk neuroblastoma and meeting the following conditions: high-risk neuroblastoma has undergone standardized treatment including induction therapy and consolidation therapy according to COG, SIOPEN or the expert consensus CCCG-NB-2021, and has entered the maintenance stage; high-risk neuroblastoma has undergone induction therapy with COG chemotherapy combined with GD2 immunotherapy and has entered the maintenance stage; any recurrence of high-risk neuroblastoma after standardized treatment; or the disease is initially determined to be in a refractory state.\n3. If it is relapsed\u002Frefractory neuroblastoma, there must be at least one measurable lesion according to RECIST 1.1 criteria;\n4. Normal major organ function, that is, meeting the following standards:\n\n(1) Blood routine test: hemoglobin \\>= 80 g\u002FL; absolute neutrophil count (ANC) \\>=0.75×10\\^9\u002FL; platelet count \\>= 75×10\\^9\u002FL; (2) Blood biochemistry test: serum albumin \\>=28 g\u002FL; total bilirubin \\\u003C= 2×upper limit of normal (ULN); aspartate aminotransferase (AST), alanine aminotransferase (ALT) \\\u003C= 3×ULN; alkaline phosphatase (ALP) \\\u003C= 3×ULN; creatinine \\\u003C= 1.5×ULN; (3) Coagulation function: international normalized ratio (INR) or prothrombin time (PT) \\\u003C= 1.5×ULN; activated partial thromboplastin time (APTT)\\\u003C=1.5×ULN; (4) Echocardiogram shows normal diastolic function of the heart, left ventricular ejection fraction (LVEF) \\>= 50%, and no severe arrhythmia; (5) No severe lung or kidney disease, no active pulmonary infection. Indoor air oxygen saturation \\>=92%; 5. Expected survival time \\>= 6 months; 6. After obtaining full informed consent from the patient and guardian, sign the informed consent form.\n\nExclusion Criteria:\n\n1. Uncontrollable active infections, or expected to receive systemic anti-infection or immunosuppressive therapy during participation in this trial;\n2. Any toxic reactions caused by previous anti-tumor treatments have not recovered to grade 1 or below (CTCAE 5.0 version) (hair loss is not restricted);\n3. Have a history of organ transplantation or are expected to undergo organ transplantation during the trial period;\n4. Highly allergic constitution;\n5. HIV infection;\n6. The researchers believe that there are other circumstances in which the subjects are not suitable to participate in this study.","1 Year",{"count":143,"type":21},15,[145,146],"PHASE1","PHASE2","This is a prospective, single-arm, open, single-center clinical trial to evaluate the safety and efficacy of autologous NK cells combined with chemotherapy and GD2 monoclonal antibody in the treatment of newly diagnosed high-risk or relapsed\u002Frefractory neuroblastoma in children. Fifteen eligible subjects are planned to be included. The objective is to evaluate the safety and efficacy of autologous NK cells combined with GD2 monoclonal antibody in the treatment of children with newly diagnosed high-risk or relapsed\u002Frefractory neuroblastoma, which is expected to be safe and effective in improving PFS and DCR in children with refractory\u002Frecurrent neuroblastoma.",[149,150,151],"Neuroblastoma","GD2 Antibody","Autologous NK Cell",[153,154,155],"neuroblastoma","GD2 antibody","autologous NK cell",{"date":157,"type":35},"2025-04-29",{"date":159,"type":21},"2025-05-01",{"date":161,"type":21},"2028-04-30",{"name":40,"class":41},{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":75,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":67},"100587267","human-genes-and-microbiota-in-early-life-100587267","NCT06926166","Human Genes and Microbiota in Early Life","Human Genes and Microbiota in Early Life (HuGME)","HuGME","Inclusion Criteria:\n\nPregnant women with \\\u003C 20 weeks of gestation Pregnant women intended to eventually deliver in Guangzhou Women and Children's medical center Permanent residengts of families intended to remain in Guangzhou with their child for ≥3 years\n\nExclusion Criteria:\n\nRefuses to have blood and stool samples stored at Born in Guangzhou cohort study Biobank.",{"count":172,"type":21},20000,"The long-term goal of the Human Genes and Microbiota in Early Life (HuGME) is to explore the short- and long-term effects of maternal microbiota during pregnancy and the microbiota colonization of their offspring early in life and their interaction with the host on maternal-offspring health consequences in later life in the born in Guangzhou cohort study in China. Identification of the effect of microbiota in early life, as well as environmental factors and microbe-host interaction, will lead to a better understanding of disease pathogenesis and provide a foundation for targeted mechanistic investigation into the consequences of microbial-host crosstalk for long-term health. It also can result in new strategies to predict and prevent diseases in later life.",[175,176,177,178,179,180,181],"Host and Microbiome","Pregnancy Outcomes","Pregnancy Complications","Neurodevelopmental Disorders","Immune Development","Childhood Obesity","Type 2 Diabetes","2025-04-07",{"date":184,"type":35},"2025-04-13",{"date":186,"type":35},"2019-04-01",{"date":188,"type":21},"2038-12-31",{"name":40,"class":41},{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":75,"sex":197,"minAge":103,"maxAge":198,"enrollmentInfo":199,"targetDuration":4,"studyType":53,"phases":201,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":213},"100477967","born-in-guangzhou-intervention-study-100477967","NCT05503849","Born In Guangzhou Intervention Study","BIGIS","Inclusion Criteria:\n\n* Pregnant women attending prenatal care at Guangzhou Women and Children's Medical Center (GWCMC) \\\u003C20 weeks' gestation\n* Pregnant women plan to deliver at GWCMC\n* Pregnant women intend to reside in Guangzhou for at least 3 years\n\nExclusion Criteria:\n\n* Multiple pregnancies\n* Existing medical conditions (uncontrolled diabetes, hypertension or thyroid disease; other serious cardiovascular diseases, respiratory or systematic disorders)\n* Use of drugs (aspirin, metformin, low molecular weight heparin)\n* Women with reading and\u002For writing difficulties\n* Women with serious mental disorders\n* Women with eating disorders","FEMALE","50 Years",{"count":200,"type":21},1160,[202],"NA","The main objective of this study is to test the efficacy of an intervention package (dietary, physical and lifestyle modification) during pregnancy in improving the clinical outcomes of mother-infant dyads.",[176,205,177],"Child Development",{"date":207,"type":35},"2025-04-10",{"date":209,"type":35},"2024-07-22",{"date":211,"type":21},"2032-09",{"name":40,"class":41},2,{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":16,"minAge":77,"maxAge":103,"enrollmentInfo":222,"targetDuration":4,"studyType":53,"phases":224,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":233,"leadSponsor":235,"locationsCount":67},"100585620","phase-3-chimeric-antigen-receptors-t-cells-for-refractoryrecurrent-lupus-nephritis-in-children-100585620","NCT06904729","Chimeric Antigen Receptors T Cells for Refractory\u002FRecurrent Lupus Nephritis in Children","An Exploratory Clinical Study of the Safety and Efficacy of CAR-T in Children With Refractory\u002FRecurrent Lupus Nephritis Disease","CAR-T","Inclusion Criteria:\n\n1. Age 6-18 years old (including critical value);\n2. Diagnosed with SLE according to the 2019 EULAR\u002FACR SLE classification criteria;\n3. According to the 2018 ISN\u002FRPS LN standards diagnosed with active Class III or IV LN, with or without a membranous component and the biopsy must be performed within 6 months prior to screening;\n4. SLEDAI-2000 score ≥8 points;\n5. Meeting the diagnosis of refractory lupus nephritis,\n\n   1. defined as treatment with two or more immunosuppressants (including glucocorticoids, cyclophosphamide, tacrolimus, mycophenolic acid analogues, leflunomide, and cyclosporine) for more than 6 months without inducing remission or relapse after remission,\n   2. accompanied by proteinuria without remission;\n6. Positive expression of CD19 in peripheral blood B cells determined by flow cytometry;\n7. Participants had good venous access, no contraindications for cell collection;\n8. Participants and their guardians sign the informed consent, understand the study procedures and participate in the clinical study voluntarily;\n9. The functions of important organs are basically normal:\n\n   1. Hematopoietic function (blood routine should meet):\n\n      * Lymphocyte count ≥1×109\u002FL,\n      * White blood cell count ≥3×109\u002FL,\n      * Neutrophil count ≥1×109\u002FL (no colony-stimulating factor treatment within 2 weeks prior to examination),\n      * Hemoglobin ≥60g\u002FL;\n   2. Liver function:\n\n      * ALT≤3×ULN (except elevated ALT caused by inflammatory myopathy),\n      * AST≤3×ULN (except for elevated AST caused by inflammatory myopathy),\n      * TBIL≤1.5×ULN (except Gilbert syndrome, total bilirubin ≤3.0×ULN);\n   3. Renal function: eGFR ≥30 ml\u002F(min.1.73m2) (Schwartz formula, except abnormal renal function by SLE);\n   4. Coagulation function:\n\n      * International standardized ratio (INR) ≤1.5×ULN,\n      * prothrombin time (PT) ≤1.5×ULN;\n   5. Heart function: hemodynamic stability;\n10. Anti-nuclear antibody (ANA) ≥1:80;\n11. Eastern Cancer Cooperation Group (ECOG) physical status score 0 to 2.\n\nExclusion Criteria:\n\n1. Received kidney transplant previously;\n2. Serious drug allergy history or allergy;\n3. Presence or suspicion of fungal, bacterial, viral or other infections that cannot be controlled or require treatment;\n4. Complicated with severe organ dysfunction of heart, liver, lung or coagulation dysfunction;\n5. Complicated with congenital immunoglobulin deficiency;\n6. Participants with infectious diseases:\n\n   1. Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBc Ab) positive and peripheral blood hepatitis B virus (HBV) DNA titer greater than the normal reference value range;\n   2. Hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C virus (HCV) RNA titer greater than the normal reference value range;\n   3. Human immunodeficiency virus (HIV) antibody positive;\n   4. Syphilis positive;\n7. Diagnosed with malignant tumors in the last five years.\n8. Suffer from severe central nervous system disease, mental illness and severe cognitive dysfunction;\n9. Participated in other clinical trials within 3 months before enrollment;\n10. Received CAR-T therapy previously;\n11. Other situations that the researcher considers unsuitable for inclusion.",{"count":223,"type":21},50,[225],"PHASE3","The goal of this prospective, open, single-arm clinical trial was to evaluate the safety and potential efficacy of CAR T cell therapy in children with refractory\u002Frecurrent lupus nephritis. The persistence and cell phenotype of CAR-T cells in vivo and CAR-T treatment-related inflammatory factors were evaluated after treatment. To explore new therapeutic methods, in order to reduce the side effects of traditional therapeutic drugs, increase curative effect, and finally make patients obtain long-term survival and improve survival quality.",[228],"Lupus Nephritis","2025-03-27",{"date":231,"type":35},"2025-04-01",{"date":159,"type":21},{"date":234,"type":21},"2029-04-30",{"name":40,"class":41},{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":243,"enrollmentInfo":244,"targetDuration":49,"studyType":23,"phases":4,"briefSummary":246,"conditions":247,"keywords":249,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":4},"100572279","long-term-renal-prognosis-of-neonatal-acute-kidney-injury-100572279","NCT06731205","Long-term Renal Prognosis of Neonatal Acute Kidney Injury","Long-term Renal Prognosis of Neonatal Acute Kidney Injury: A Multicenter, Prospective Cohort Study","Inclusion Criteria:\n\n* Delivered in this hospital and subsequently admitted to the NICU during the study period;\n* Diagnosed with neonatal AKI according to the 2015 KDIGO neonatal AKI criteria;\n* Age \\\u003C28 days.\n\nExclusion Criteria:\n\n* Severe hydronephrosis diagnosed by prenatal renal ultrasound;\n* Patients with congenital urinary malformations, including solitary kidney, cystic dysplasia, multicystic dysplastic kidney, renal dysplasia, and obstructive uropathy;\n* Newborns who required congenital heart surgery within the first 7 days after birth;\n* Newborns whose mothers had a history of renal failure;\n* Death within 48 hours after birth;\n* Other genetic syndromes or medical conditions were not eligible for inclusion according to the attending neonatologist's judgment.","28 Days",{"count":245,"type":21},1852,"The goal of this observational study is to conduct a multicenter, prospective neonatal acute kidney injury (AKI) follow-up cohort to describe the clinical characteristics of chronic kidney disease (CKD) in AKI cases within 1 year of follow-up and screen for effective biomarkers that can early warn of CKD progression. Ultimately, a neonatal AKI adverse prognosis warning model based on multidimensional data will be established to provide new data and new models for CKD management.",[248],"Neonatal Acute Kidney Injury",[248,250,251,252],"Long-Term Prognosis","Prognosis and Predictive Factors","Biomarkers","2024-12-29",{"date":255,"type":35},"2024-12-31",{"date":257,"type":21},"2025-01-01",{"date":259,"type":21},"2028-12-31",{"name":40,"class":41},{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":78,"enrollmentInfo":269,"targetDuration":4,"studyType":53,"phases":271,"briefSummary":272,"conditions":273,"keywords":275,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":279,"startDateStruct":280,"completionDateStruct":281,"leadSponsor":282,"locationsCount":4},"100572278","phase-2-human-umbilical-cord-mesenchymal-stem-cells-for-alport-syndrome-100572278","NCT06731192","Human Umbilical Cord Mesenchymal Stem Cells for Alport Syndrome","Human Umbilical Cord Mesenchymal Stem Cells for Alport Syndrome: Α Prospective Randomized, Single-blind, Placebo-controlled, Single-center Clinical Trial","HUCMSC","Inclusion Criteria:\n\n* 3 years old ≤Age ≤ 12 years old;\n* Meet the diagnostic criteria of Alport syndrome;\n* Positive proteinuria or combined hematuria;\n* Chronic kidney disease (CKD) stage: I-III stage children, that is, glomerular filtration rate greater than 60 ml\u002Fmin.1.73m2;\n* No history of infectious diseases within 1 week before treatment;\n* Negative infectious disease screening;\n* No allergic state and related clinical manifestations;\n* Signed informed consent (children or their families).\n\nExclusion Criteria:\n\n* Age \\\u003C3 years or \\>12 years old;\n* Alport syndrome patients with only microscopic hematuria and normal glomerular filtration rate;\n* Patients with significantly reduced renal function, chronic kidney disease stage IV or V, Alport syndrome;\n* Patients with other renal diseases;\n* Have a history of severe allergic reactions or be allergic to 2 or more foods or drugs;\n* Known allergy to stem cells or stem cell-derived products or ingredients in stem cell preparations;\n* Have severe heart, liver, lung and other organ dysfunction or have tumors;\n* Those with developmental malformations of the urinary system;\n* Those with autoimmune diseases and regular use of immunosuppressants;\n* Those with serious infectious diseases that are not under control;\n* Those with a history of infectious diseases such as HBV, HCV, HIV, syphilis;\n* History of surgery or acute trauma or blood loss exceeding 200ml within 3 months;\n* Participated in other clinical studies within 3 months;\n* Have received any cell product or derivative product treatment within 12 months;\n* Other circumstances that the researcher deems inappropriate for inclusion.",{"count":270,"type":21},40,[146,225],"The goal of this clinical trial is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in the treatment of Alport syndrome (AS) in a randomized, single-blind, placebo-controlled trial, to provide a clinical basis for the development of stem cell products for the treatment of AS, and to further clarify the therapeutic effect of hUC-MSC in the treatment of AS.",[274],"Alport Syndrome",[276,277,278],"Alport syndrome","Human Umbilical Cord Mesenchymal Stem Cells","Randomized Clinical Trial",{"date":255,"type":35},{"date":257,"type":21},{"date":259,"type":21},{"name":40,"class":41},{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":16,"minAge":141,"maxAge":103,"enrollmentInfo":290,"targetDuration":4,"studyType":53,"phases":292,"briefSummary":293,"conditions":294,"keywords":296,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":298,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":67},"100573938","phase-1-cd19cd22-car-t-cell-therapy-in-mrd-positive-b-lineage-acute-lymphoblastic-leukemia-in-children-100573938","NCT06752785","CD19\u002FCD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.","Clinical Study on the Safety and Efficacy of CD19\u002FCD22 CAR-T Cell Therapy in MRD-Positive B-lineage Acute Lymphoblastic Leukemia in Children.","Inclusion Criteria:\n\n1. Parents or legal guardians fully understand, are informed of this study and sign the informed consent form (ICF); are willing to follow and can complete all test procedures.\n2. Chinese children aged 1-18 years old at the time of screening, regardless of gender, with a body weight ≥ 10 kg.\n3. Bone marrow examination confirms that MRD is still positive on the 46th day after induction remission.\n4. Tumor cells in the bone marrow (BM) or peripheral blood (PB) express CD19\u002FCD22 within 3 months before screening.\n5. Good organ function, which needs to meet the following criteria: (1)ALT ≤ 5 times the upper limit of normal value (ULN); (2)total bilirubin ≤ 2 times ULN (Gilbert's syndrome ≤ 3 times ULN); (3)without \\> grade 1 dyspnea when not inhaling oxygen, and oxygen saturation \\> 95%; (4)left ventricular ejection fraction (LVEF) ≥ 50%; (5)serum creatinine ≤ 1.5 times ULN.\n6. Karnofsky score (≥ 16 years old) ≥ 70 or Lansky (\\\u003C 16 years old) score ≥ 50.\n7. Expected survival period of at least 12 weeks.\n8. Have sufficient venous access (for apheresis or venous blood sampling), and have no other contraindications for blood cell separation.\n\nExclusion Criteria:\n\n1. Have genetic diseases, except Down syndrome.\n2. Have a history of other malignancies or have other malignancies simultaneously.\n3. Meet any of the following conditions: (1)hepatitis B surface antigen (HBsAg) positive or HBV DNA quantification higher than the upper limit of normal value; (2)hepatitis C antibody (HCV Ab) positive and HCV RNA quantification higher than the upper limit of normal value; (3)human immunodeficiency virus antibody (HIV-Ab) positive; (4)Treponema pallidum antibody (TP-Ab) positive; (5)EBV DNA higher than the upper limit of normal value; (6)cytomegalovirus DNA higher than the upper limit of normal value.\n4. Have or are suspected to have uncontrolled or require intravenous drug treatment for fungal, bacterial, viral or other infections.\n5. Long-acting G-CSF is prohibited within 21 days before screening, and short-acting G-CSF is prohibited within 7 days before screening.\n6. Have active central nervous system leukemia.\n7. Are allergic to albumin and aminoglycoside antibiotics.\n8. Have undergone organ transplantation (except hematopoietic stem cell transplantation).\n9. Have participated in other interventional clinical studies within 3 months before screening (received active test drug treatment), or intend to participate in another clinical trial or receive anti-tumor treatment other than that specified in the protocol during the entire study period.\n10. Cannot tolerate chemotherapy and cytokine storm due to impaired function of important organs.\n11. Other situations that the investigator deems not suitable for participating in this clinical trial.",{"count":291,"type":21},10,[145],"In this study, CD19\u002FCD22 dual-target CAR-T therapy will be carried out among children patients who are still positive after induction remission, and subsequent chemotherapy will continue after CAR-T cells exert their functions. This study intends to use retroviral vector-based tandem CAR-T cells targeting CD19\u002FCD22 to treat MRD-positive ALL. The CAR-T cells were provided by Shenzhen Cell Valley. The results of the research team from Stanford University School of Medicine in the United States have already demonstrated the feasibility and safety of producing bispecific CD19\u002FCD22.BB.z-CAR T cells in a closed system as well as the high clinical activity shown in the treatment of CAR19-resistant B-ALL (B-lineage acute lymphoblastic leukemia) and LBCL (Large B-cell lymphoma). The investigators look forward to expanding the application of CAR-T cells in MRD positive B-ALL through this clinical study on safety and efficacy and greatly improving the prognosis of children patients with this type of B-ALL.",[295],"Acute Lymphoblastic Leukemia",[297],"B-ALL, CAR-T",{"date":255,"type":35},{"date":300,"type":35},"2024-10-01",{"date":302,"type":21},"2028-06-30",{"name":40,"class":41},{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":11,"sex":16,"minAge":310,"maxAge":311,"enrollmentInfo":312,"targetDuration":4,"studyType":53,"phases":314,"briefSummary":315,"conditions":316,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":323,"leadSponsor":325,"locationsCount":213},"100572534","clinical-study-of-super-transplantation-in-the-treatment-of-severe--thalassemia-100572534","NCT06734520","Clinical Study of Super Transplantation in the Treatment of Severe β-thalassemia","Inclusion Criteria:\n\n1. Diagnosis of severe β -thalassemia\n2. Age between 7-10 years old, male and female; Weight \\\u003C 40kg\n3. The patient has or does not have an HLA-compatible or semi-compatible donor, but unconditional transplantation or refusal of blood stem cell transplantation; Patients with thalassemia gene therapy without conditions or refusal;\n4. There are fully compatible or incompatible HLA donors, and the physical examination meets the donor conditions;\n5. The patient and family members agree to receive hypertransplant therapy and sign a written informed consent prior to the transplant trial.\n\nExclusion Criteria:\n\n1. Mental patients;\n2. Participants in other drug clinical trials within the past 1 month;\n3. There are no suitable HLA-incompatible donors.\n4. Other researchers decide that it is not suitable to participate in this researcher.","7 Years","10 Years",{"count":313,"type":21},3,[202],"This is a single-arm, open label, phase 1 study in subjects with beta-thalassemia. This study will evaluate the safety and efficacy of preconditioning-free super-transplantation on beta-thalassemia pediatric patients.",[317,318],"Thalassemia Majors (Beta-Thalassemia Major)","Haplo-identical Donors","2024-12-12",{"date":321,"type":35},"2024-12-16",{"date":300,"type":35},{"date":324,"type":21},"2029-07-01",{"name":40,"class":41},{"id":327,"slug":328,"hasResults":11,"nctId":329,"briefTitle":330,"officialTitle":331,"acronym":4,"eligibilityCriteria":332,"healthyVolunteers":11,"sex":197,"minAge":103,"maxAge":333,"enrollmentInfo":334,"targetDuration":4,"studyType":53,"phases":336,"briefSummary":337,"conditions":338,"keywords":341,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":350,"leadSponsor":352,"locationsCount":4},"100572435","phase-2-a-study-evaluating-the-efficacy-and-safety-of-de-trastuzumab-t-dxd-in-combination-with-immunotherapy-for-the-neoadjuvant-treatment-of-hr-positive-her2-low-expressing-chinese-patients-with-early-stage-breast-cancer-100572435","NCT06733233","A Study Evaluating the Efficacy and Safety of De Trastuzumab (T-DXd) in Combination with Immunotherapy for the Neoadjuvant Treatment of HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer","A Multicenter, Prospective Phase II Single-arm Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with T-DXd in Combination with an Immune Checkpoint Inhibitor in HR-positive HER2 Low-expressing Chinese Patients with Early-stage Breast Cancer","Inclusion Criteria:\n\n1. Adults between the ages of 18 and 70 at the time of signing the informed consent form.\n2. An Eastern Cooperative Oncology Group (ECOG) score of 0 to 1.\n3. Previously untreated, operable invasive breast cancer measuring greater than 2.0 centimeters (cT2) with positive clinical lymph nodes (cN1\u002FcN2); or clinically staged T3-T4, clinically lymph node-negative (N0) or clinically lymph node-positive (cN1\u002FcN2) without distal metastases.\n4. Tumors with low levels of HER2 expression by immunohistochemistry (IHC), defined as IHC 1+ or IHC 2+ and FISH negative.\n5. Tumor documented as HR-positive (ER and\u002For PgR-positive \\[ER or PgR ≥1%\\] by local assessment according to ASCO-CAP guidelines).\n6. Patients who agree to undergo surgical treatment for breast cancer when they meet surgical criteria after neoadjuvant therapy.\n\nExclusion Criteria:\n\n1. Stage IV (metastatic) breast cancer and bilateral breast cancer\n2. Previous history of invasive breast cancer.\n3. Previous history of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS)\n4. Other malignant tumors within 5 years, excluding cured carcinoma in situ of the cervix and non-melanoma skin cancers.","70 Years",{"count":335,"type":21},23,[146],"This is a prospective, open-label, multicenter, single-arm clinical study designed to compare the efficacy and safety of neoadjuvant treatment with T-DXd in combination with an immune checkpoint inhibitor in patients with primary intermediate- to high-risk HR-positive, HER2-overexpressing early-stage breast cancer.",[339,340],"Breast Cancer, Estrogen Receptor-Positive","HER2 Low Breast Cancer",[342,343,344,345],"Breast cancer","immunotherapy","DS8201","Neoadjuvant","2024-12-10",{"date":348,"type":35},"2024-12-13",{"date":257,"type":21},{"date":351,"type":21},"2029-01-01",{"name":40,"class":41},{"id":354,"slug":355,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":357,"acronym":358,"eligibilityCriteria":359,"healthyVolunteers":75,"sex":197,"minAge":360,"maxAge":361,"enrollmentInfo":362,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":364,"conditions":365,"keywords":368,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":374,"lastUpdatePostDateStruct":375,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":379,"locationsCount":67},"100334345","maternal-grandmothers-in-the-born-in-guangzhou-cohort-study-100334345","NCT03633162","Maternal Grandmothers in the Born in Guangzhou Cohort Study","MGBIG","Inclusion Criteria:\n\n1. Maternal Grandmother' grandchildren delivered in Guangzhou Women and Children's Medical Center\n2. Baseline information of maternal grandmother's daughter during pregnancy available\n\nExclusion Criteria:\n\n1. Significant cardiovascular abnormalities\n2. Intelligent obstacle, intellectual disabilities or gawkish condition","36 Years","100 Years",{"count":363,"type":21},5000,"The MGBIG is a study exploring cross-generational effects in 5000 women and their children and grandchildren located in Guangzhou, China. Its initial aim is to facilitate research on understanding the interplay between genes and environmental factors on disease etiology and on explaining the cause of the disease from the perspective of \"grandmother-mother-child\" heredity. Data are collected regarding environmental exposures, lifestyle, and social support on grandmother from birth to old age. Biological samples including blood and tissue samples are collected.",[366,179,180,175,367],"Hereditary Transmission","Neurodevelopment",[369,370,371,372,373],"Maternal Grandmother","Genes","Immune","Cohort","Child development","2024-09-27",{"date":300,"type":35},{"date":377,"type":35},"2018-05-21",{"date":188,"type":21},{"name":40,"class":41},{"id":381,"slug":382,"hasResults":11,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":11,"sex":16,"minAge":141,"maxAge":387,"enrollmentInfo":388,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":390,"conditions":391,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":67},"100560250","adding-of-naxitamb-in-induction-therapy-for-high-risk-neuroblastoma-100560250","NCT06574698","Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma","Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma: A Prospective, Single-Arm Clinical Study","Inclusion Criteria:\n\nNeuroblastoma patients who meet certain criteria are eligible for enrollment in the following stages of diagnosis:\n\n1. Children with newly diagnosed stage 4 neuroblastoma according to the International Neuroblastoma Staging System (INSS) who meet the following criteria are eligible for enrollment: i. Age \\> 18 months (\\> 547 days) regardless of biological characteristics; or ii. Age 12-18 months (365-547 days), with one of the following three unfavorable biological characteristics (MYCN amplification, pathological type of poor histopathological prognosis, and\u002For DNA index = 1); or iii. MYCN amplification (MYCN signal increase \\> 4 times compared to reference signal) regardless of age or other biological characteristics.\n2. Children with newly diagnosed stage 3 INSS neuroblastoma who meet the following criteria are eligible for enrollment: i. MYCN amplification (MYCN signal increase \\> 4 times compared to reference signal) regardless of age or other biological characteristics; or ii. Age \\> 18 months (\\> 547 days), with pathological type of poor histopathological prognosis regardless of MYCN status.\n3. Children with newly diagnosed stage 2A\u002F2B INSS neuroblastoma with MYCN amplification (MYCN signal increase \\> 4 times compared to reference signal) regardless of age or other biological characteristics. The subject must be aged ≤ 21 years at the time of initial diagnosis, and must be aged \\> 12 months at the time of enrollment.\n\nExclusion criteria:\n\nInfants less than 1 year old, those aged 12-18 months, INSS stage 4, and all INSS stage 3 patients with favorable biological characteristics (i.e., non-amplified MYCN, good pathological histopathological prognosis, and DNA index \\>1) are not eligible.\n\nSubjects who have received immunosuppressive treatment (excluding local steroids) within the last 4 weeks prior to enrollment. Subjects who are currently receiving any investigational drug.\n\nAny other medical condition that, in the opinion of the investigator, may interfere with the interpretation of results or affect the subject's ability to provide informed consent, the legal guardian's ability to provide informed consent, and the subject's cooperation and participation in the study, including but not limited to malabsorption syndrome, mental illness, or substance abuse. Subjects with significant comorbidities (any serious medical condition unrelated to cancer or its treatment that is not covered by the detailed exclusion criteria and is expected to interfere with the investigation drug(s) action or significantly increase the severity of the trial treatment toxicity)","21 Years",{"count":389,"type":21},64,"To explore the efficacy of adding anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy for newly diagnosed high risk neuroblastoma patients. To investigate wether anding Naxitamab in the induction phase will improve the response rate at the end of induction therapy and further improve the overall survival rate.",[149,392],"GD2 Antibody (Naxitamab)","2024-08-24",{"date":395,"type":35},"2024-08-28",{"date":397,"type":35},"2024-05-06",{"date":399,"type":21},"2032-12-31",{"name":40,"class":41},{"id":402,"slug":403,"hasResults":11,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":407,"eligibilityCriteria":408,"healthyVolunteers":75,"sex":16,"minAge":4,"maxAge":103,"enrollmentInfo":409,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":411,"conditions":412,"keywords":420,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":428,"locationsCount":67},"100342698","offspring-born-to-mothers-with-polycystic-ovary-syndrome-in-guangzhou-cohort-study-100342698","NCT03742011","Offspring Born to Mothers With Polycystic Ovary Syndrome in Guangzhou Cohort Study","Health of Offspring Born to Mothers With Polycystic Ovary Syndrome in Guangzhou Cohort Study","PCOS-BIG","Inclusion Criteria:\n\n* Offspring born to women diagnosed with PCOS\n* Offspring born to women with \\\u003C20 weeks of gestation, intended to eventually deliver in Guangzhou Women and Children's Medical Center\n* Permanent residents or families intended to remain in Guangzhou for ≥3 years\n\nExclusion Criteria:\n\n* None",{"count":410,"type":21},2000,"The Offspring Born to Mothers with Polycystic Ovary Syndrome in Guangzhou Cohort study (PCOS-BIG) was established to investigate the short- and long-term effects of intrauterine exposure to maternal PCOS on the health of offspring in Guangzhou, China. Data are collected regarding maternal PCOS subtypes, nursing, diet and education as well as health outcomes in their later life. Biological samples including blood and tissue samples are also collected from participants.",[413,414,415,416,417,418,419],"PCOS","Offspring, Adult","Hyperandrogenism","Epigenetics","Insulin Resistance","Endocrine Disorder","Metabolic Disturbance",[413,415,416,421],"Glucolipid metabolism disorder","2024-02-22",{"date":424,"type":35},"2024-02-26",{"date":426,"type":35},"2012-02-01",{"date":188,"type":21},{"name":40,"class":41},{"id":430,"slug":431,"hasResults":11,"nctId":432,"briefTitle":433,"officialTitle":433,"acronym":434,"eligibilityCriteria":435,"healthyVolunteers":75,"sex":16,"minAge":4,"maxAge":103,"enrollmentInfo":436,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":437,"conditions":438,"keywords":440,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":444,"startDateStruct":445,"completionDateStruct":446,"leadSponsor":447,"locationsCount":67},"100337045","preterm-birth-cohort-study-in-guangzhou-100337045","NCT03668327","Preterm Birth Cohort Study in Guangzhou","PBCSG","Inclusion Criteria:\n\n1. Born before 37 weeks of gestation\n2. Born in Guangzhou Women and Children's Medical Center\n3. Intended to remain in Guangzhou for more than 3 years\n\nExclusion Criteria:\n\n1. Multiple birth\n2. Stillbirth\n3. With major congenital abnormalities",{"count":363,"type":21},"The Preterm Birth Cohort Study in Guangzhou (PBCSG) aims to explore the impact of genetic and environmental factors including life styles on preterm birth, to examine the interaction effect between these factors, and to follow up the short-term and long-term outcomes of preterm childrens.",[439,367,179,175],"Preterm Birth",[441,372,442,443],"Preterm","Early development","Child",{"date":424,"type":35},{"date":426,"type":35},{"date":188,"type":21},{"name":40,"class":41},{"id":449,"slug":450,"hasResults":11,"nctId":451,"briefTitle":452,"officialTitle":453,"acronym":454,"eligibilityCriteria":455,"healthyVolunteers":75,"sex":16,"minAge":4,"maxAge":103,"enrollmentInfo":456,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":458,"conditions":459,"keywords":462,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":465,"startDateStruct":466,"completionDateStruct":467,"leadSponsor":468,"locationsCount":67},"100335700","ivf-offspring-born-in-guangzhou-100335700","NCT03650829","IVF Offspring Born in Guangzhou","IVF Offspring Born in Guangzhou Cohort Study","IVF-BIG","Inclusion Criteria:\n\n* Pregnant women with \\\u003C20 weeks of gestation\n* Pregnant women intended to eventually deliver in Guangzhou Women and Children's Medical Center\n* Permanent residents or families intended to remain in Guangzhou with their child for ≥3 years\n* Pregnant women conceived by assited reproductive technology\n\nExclusion Criteria:\n\n• None",{"count":457,"type":21},3000,"The IVF Offspring Born in Guangzhou Cohort Study (IVF-BIG) was established to investigate the short- and long-term effects of exposure in early life on the health of mothers and offspring in Guangzhou, China. Data are collected regarding assisted reproductive technology (ART), environmental, occupational and lifestyle exposures as well as health outcomes in their later life. Biological samples including blood and tissue samples are also collected from participants.",[460,414,461,175,367],"ART","Genetics",[460,463,464,372],"Offspring","Development",{"date":424,"type":35},{"date":426,"type":35},{"date":188,"type":21},{"name":40,"class":41},{"id":470,"slug":471,"hasResults":11,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":475,"eligibilityCriteria":476,"healthyVolunteers":75,"sex":16,"minAge":4,"maxAge":103,"enrollmentInfo":477,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":479,"conditions":480,"keywords":482,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":485,"startDateStruct":486,"completionDateStruct":487,"leadSponsor":488,"locationsCount":67},"100311188","twins-born-in-guangzhou-100311188","NCT03331133","Twins Born in Guangzhou","Twins Born in Guangzhou Cohort Study","2-BIG","Inclusion Criteria:\n\n1. Live twins delivered in Guangzhou Women and Children's Medical Center\n2. Permanent residents or families intended to remain in Guangzhou with their children for no less than 3 years\n3. Baseline information during pregnancy available",{"count":478,"type":21},1000,"The 2-BIG is a twin birth cohort study located in Guangzhou, China.Its initial aim is to facilitate research on understanding the interplay between genes and environmental factors on disease etiology. Data are collected regarding environmental, family and lifestyle exposures on twins from birth to 18 years old. Biological samples including blood and tissue samples are also collected from the twins and their parents.",[481,179,180,175,367],"Twin Diseases",[483,484,372],"Twin","Early Development",{"date":424,"type":35},{"date":426,"type":35},{"date":188,"type":21},{"name":40,"class":41},{"id":490,"slug":491,"hasResults":11,"nctId":492,"briefTitle":493,"officialTitle":493,"acronym":494,"eligibilityCriteria":495,"healthyVolunteers":75,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":496,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":498,"conditions":499,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":501,"startDateStruct":502,"completionDateStruct":503,"leadSponsor":505,"locationsCount":67},"100249529","the-born-in-guangzhou-cohort-study-bigcs-100249529","NCT02526901","The Born in Guangzhou Cohort Study (BIGCS)","BIGCS","Inclusion Criteria:\n\n* Pregnant women with \\\u003C20 weeks of gestation\n* Pregnant women intended to eventually deliver in Guangzhou Women and Children's Medical Center\n* Permanent residents or families intended to remain in Guangzhou with their child for ≥3 years",{"count":497,"type":21},30000,"The Born in Guangzhou Cohort Study (BIGCS) was established to investigate the short- and long-term effects of exposure in early life on health consequences in Guangzhou, China. Data are collected regarding environmental, occupational and lifestyle exposures as well as health outcomes in later life. Biological samples including blood and tissue samples are also collected from the participants.",[500,176,367,179,180,175],"Intrauterine Hyperglycemia",{"date":424,"type":35},{"date":426,"type":4},{"date":504,"type":21},"2030-12-31",{"name":40,"class":41},{"id":507,"slug":508,"hasResults":11,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":512,"eligibilityCriteria":513,"healthyVolunteers":75,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":514,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":516,"conditions":517,"keywords":520,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":525,"startDateStruct":527,"completionDateStruct":528,"leadSponsor":529,"locationsCount":67},"100403176","gdm-and-its-consequences-in-mothers-and-offsprings-100403176","NCT04529889","GDM and Its Consequences in Mothers and Offsprings","Gestational Diabetes Mellitus and Its Consequences in Mothers and Offsprings","GDMCMO","Inclusion Criteria:\n\n1. Pregnant women diagnosed with gestational diabetes mellitus\n2. Pregnant women intended to eventually deliver in Guangzhou Women and Children's Medical Center\n3. Permanent residents or families intended to remain in Guangzhou with their child for no less than 3 years\n\nExclusion Criteria:\n\n1. Women with pre-gestational diabetes mellitus\n2. Women with chronic hypertension or kidney disease",{"count":515,"type":21},7000,"Gestational diabetes mellitus (GDM) is one of the most common disorders which occured during pregnancy. GDM is not only associated with short-term maternal and fetal adverse outcomes, but also related to a wide range of long-term consequences for both mother and child. The GDM and Its Consequences for mothers and offsprings (GDMCMO) aims to establish a cohort to follow both maternal and offsprings'short-term and long-term outcomes, including fetal malformations including congenital heart diseases, birth weight, preterm birth, caesarean section delivery, body growth and neurodevelopment after birth, obesity, type 2 diabetes and impaired insulin sensitivity and secretion, lung health and allergic diseases later in life for offspring, as well as future type 2 diabetes and cardiovascular risk factors for mother after delivery. Biological samples including blood and tissue samples of mothers and children are also collected during pregnancy and after delivery.",[518,519,367,179,180,175],"Gestational Diabetes Mellitus","Pregnancy Outcome",[521,522,523,372],"Hyperglycaemia","Maternal health","Children","2023-09-11",{"date":526,"type":35},"2023-09-13",{"date":426,"type":35},{"date":188,"type":21},{"name":40,"class":41},{"id":531,"slug":532,"hasResults":11,"nctId":533,"briefTitle":534,"officialTitle":534,"acronym":4,"eligibilityCriteria":535,"healthyVolunteers":75,"sex":197,"minAge":4,"maxAge":4,"enrollmentInfo":536,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":537,"conditions":538,"keywords":541,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":524,"lastUpdatePostDateStruct":546,"startDateStruct":547,"completionDateStruct":548,"leadSponsor":549,"locationsCount":67},"100400809","peripartum-mental-health-cohort-study-in-guangzhou-100400809","NCT04499066","Peripartum Mental Health Cohort Study in Guangzhou","Inclusion Criteria:\n\n1. Pregnant women with \\\u003C20 weeks of gestation\n2. Pregnant women intended to eventually deliver in Guangzhou Women and Children's Medical Center\n3. Permanent residents or families intended to remain in Guangzhou with their child for more than 3 years\n\nExclusion Criteria:\n\n1. Combined with heart disease, hypertension, diabetes or hyperthyroidism\n2. Taking anti-depressants and other treatments for depression\n3. Participants was in infection status when the biological samples were collected",{"count":457,"type":21},"The purpose of this study is to determine the incidence,development trajectory and risk factors of the main peripartum mental health problems as well as explore its adverse outcomes.",[539,540],"Depression","Anxiety",[542,543,544,545,372],"Peripartum","Mental health","Risk factors","Pregnancy outcome",{"date":526,"type":35},{"date":426,"type":35},{"date":188,"type":21},{"name":40,"class":41},{"id":551,"slug":552,"hasResults":11,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":556,"eligibilityCriteria":557,"healthyVolunteers":11,"sex":16,"minAge":558,"maxAge":18,"enrollmentInfo":559,"targetDuration":4,"studyType":53,"phases":561,"briefSummary":562,"conditions":563,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":565,"lastUpdatePostDateStruct":566,"startDateStruct":568,"completionDateStruct":570,"leadSponsor":572,"locationsCount":4},"100486931","timing-of-operation-in-children-with-a-prenatal-diagnosis-of-choledochal-cyst-100486931","NCT05620485","Timing of Operation in Children With a Prenatal Diagnosis of Choledochal Cyst","Timing of Operation in Children With a Prenatal Diagnosis of Choledochal Cyst：A Single-center Prospective Study","CDCPS","Inclusion Criteria:\n\n1. Infants with a prenatal and postnatal diagnosis with CDC\n2. Prenatal and postnatal hepatobiliary ultrasound data were complete\n3. Age of visit \\\u003C 3 months\n\nExclusion Criteria:\n\nUnable to tolerate surgery after birth","0 Months",{"count":560,"type":21},30,[202],"In this prospective study, we tried to select the operation time according to the cyst size and evaluate the treatment effect.",[564],"Choledochal Cyst","2022-11-12",{"date":567,"type":35},"2022-11-17",{"date":569,"type":21},"2022-11-15",{"date":571,"type":21},"2026-11-15",{"name":40,"class":41},{"id":574,"slug":575,"hasResults":11,"nctId":576,"briefTitle":577,"officialTitle":578,"acronym":4,"eligibilityCriteria":579,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":103,"enrollmentInfo":580,"targetDuration":582,"studyType":23,"phases":4,"briefSummary":583,"conditions":584,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":590,"startDateStruct":592,"completionDateStruct":594,"leadSponsor":596,"locationsCount":67},"100316365","diagnosis-and-management-of-intrauterine-growth-restriction-and-congenital-anomalies-100316365","NCT03398629","Diagnosis and Management of Intrauterine Growth Restriction and Congenital Anomalies","Diagnosis and Management of Intrauterine Growth Restriction, Structural Anomalies and Chromosomal Anomalies: A Prospective Cohort Study","Inclusion Criteria:\n\nAll pregnant women who present to Guangzhou Women and Children's Medical Center meeting one of the following prenatal diagnoses and neonates\u002Finfants who are diagnosed as one of the following anomalies will be invited to participate:\n\n1. Intrauterine growth restriction (IUGR)\n2. Structural anomaly\n3. Chromosomal anomaly\n\nExclusion Criteria:\n\n1. Pregnant women who don't agree to participate;\n2. Pregnant women delivering babies at other hospitals.\n3. Prenatally suspected anomalies that are not confirmed by postnatal diagnosis.",{"count":581,"type":21},10000,"20 Years","The purpose of this prospective cohort study is to build a large platform that includes clinical information (prenatal diagnosis and postnatal follow-up data) and biological specimen banks of fetuses\u002Finfants with IUGR or congenital anomalies, which provide vital support and research foundation for accurate diagnosis, precision treatment and meticulous management.",[585,586,587,588],"Intrauterine Growth Restriction","Fetal Anomaly","Chromosomal Anomalies","Pregnancy","2019-06-03",{"date":591,"type":35},"2019-06-04",{"date":593,"type":35},"2019-05-01",{"date":595,"type":21},"2038-03-01",{"name":40,"class":41},""]